Published online before print January 23, 2006, doi: 10.1161/01.HYP.0000200748.73303.a6
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2006;47:337.)
© 2006 American Heart Association, Inc.
Editorial Commentaries |
Regulator of G-Protein Signaling-2 as a Candidate Gene
The Road to Hypertension or Just Another Roadside Marker?
From the Cell Biology and Vascular Biology Research Groups, Robarts Research Institute, London, Ontario, Canada.
Correspondence to Dr Ross D. Feldman, Cell Biology and Vascular Biology Research Groups, Robarts Research Institute, PO Box 5015, 100 Perth Drive, London, Ontario Canada, N6A 5K8. E-mail feldmanr@lhsc.on.ca
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
The "mosaic theory" of hypertension has been the prevailing dogma since its enunciation more than a half century ago. However, the ongoing search has been to determine which of the myriad of alterations in blood pressure regulatory systems occurs earliest in the process and are critical in the maintenance of the hypertensive state. Much of that focus has been directed to the determinants of increased peripheral resistance—perhaps the hallmark of the hypertensive state. The mechanisms underlying this abnormality reflect a combination of both structural and functional factors.
From a functional perspective, peripheral resistance reflects a net balance between vasoconstrictor and vasodilator mechanisms. Defects in vasodilator mechanisms and enhancement of vasoconstrictor mechanisms have been described in human hypertension as well as in animal models. Central among these mechanisms have been alterations in G-protein-coupled receptor (GPCR) signaling pathways.
Alterations in GPCR-signaling pathways in the hypertensive state are probably best explained by alterations downstream from the receptor. For those GPCRs linked to Gs and adenylyl cyclase activation, the impairment in GPCR/ G-protein "coupling" reflects both decreased G-protein function as well as the impact of increased expression/activity of the G-protein receptor kinases that interdict GPCR/G-protein signaling.1 For those mechanisms linked to vasoconstrictor process (via either Gi or Gq) the alterations also appear to be generalized across a range of receptors, consistent with a "downstream" effect.2 For Gi-linked systems, enhanced Gi function has been described in hypertension.3 However, for Gq-linked systems the locus of the defect is less clear.
Alterations in GPCR
Related Article:
Hypertension 2006 47: 415-420.
This article has been cited by other articles:
 |
|
 |
|
  D. A. Dalmas, M. S. Scicchitano, Y. Chen, J. Kane, R. Mirabile, L. W. Schwartz, H. C. Thomas, and R. W. Boyce Transcriptional Profiling of Laser Capture Microdissected Rat Arterial Elements: Fenoldopam-induced Vascular Toxicity as a Model System Toxicol Pathol, April 1, 2008; 36(3): 496 - 519. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Harris, H. I. Cohn, S. Pesant, R.-H. Zhou, and A. D. Eckhart Vascular smooth muscle Gq signaling is involved in high blood pressure in both induced renal and genetic vascular smooth muscle-derived models of hypertension Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H3072 - H3079. [Abstract] [Full Text] [PDF]
|
|